Description
Recombinant Human TrkA/NTRK1 Protein (aa 194-413, His Tag)(Active) | PKSH031278 | Gentaur US, UK & Europe Disrtribition
Synonyms: MTC;p140-TrkA;TRK;Trk-A;TRK1;TRKA
Active Protein: Active protein
Activity: A DNA sequence encoding the amino acid sequence (Pro 194-Glu 413) of human NTRK1 (NP_002520.2), corresponding to the Ig-like C2-type 1 & 2 domains, was expressed and purified, with a N-terminal polyhistidine tag.
Protein Construction: A DNA sequence encoding the amino acid sequence (Pro 194-Glu 413) of human NTRK1 (NP_002520.2), corresponding to the Ig-like C2-type 1 & 2 domains, was expressed and purified, with a N-terminal polyhistidine tag.
Fusion Tag: N-His
Species: Human
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 26 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family. It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. Isoform TrkA-I is found in most non-neuronal tissues. Isoform TrkA-II is primarily expressed in neuronal cells. TrkA-III is specifically expressed by pluripotent neural stem and neural crest progenitors. The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer. It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas. TRKA is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma.Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: Neuroscience, Cancer, metabolism
